Enlivex Therapeutics Ltd
(ENLV)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
by (Cboe BZX)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
[[ item.lastPriceExt ]]
[[ item.priceChangeExt ]]
([[ item.percentChangeExt ]])
[[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 03-2018 | 12-2017 | 09-2017 | 06-2017 | 03-2017 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -1,025 | -2,504 | -1,709 | -4,305 | -2,672 |
| Depreciation Amortization | 33 | 83 | 59 | 64 | 5 |
| Accounts receivable | 50 | -7 | -180 | 321 | -22 |
| Accounts payable and accrued liabilities | 4 | -5 | -11 | -1,139 | -313 |
| Other Working Capital | 94 | -23 | -33 | -800 | -333 |
| Other Operating Activity | -22 | 152 | 367 | 1,153 | 566 |
| Operating Cash Flow | $-866 | $-2,304 | $-1,507 | $-4,706 | $-2,769 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -139 | -130 | -91 | -2 | -2 |
| Sale Of Investment | N/A | N/A | N/A | 3,000 | N/A |
| Investing Cash Flow | $-139 | $-130 | $-91 | $2,998 | $-2 |
| Cash Flows From Financing Activities | |||||
| Other Financing Activity | 0 | 8,055 | 6,018 | 0 | 0 |
| Financing Cash Flow | $N/A | $8,055 | $6,018 | $N/A | $N/A |
| Exchange Rate Effect | -105 | 364 | 199 | N/A | N/A |
| Beginning Cash Position | 9,005 | 3,020 | 3,020 | 6,871 | 6,871 |
| End Cash Position | 7,895 | 9,005 | 7,639 | 5,163 | 4,100 |
| Net Cash Flow | $-1,110 | $5,985 | $4,619 | $-1,708 | $-2,771 |
| Free Cash Flow | |||||
| Operating Cash Flow | -866 | -2,304 | -1,507 | -4,706 | -2,769 |
| Capital Expenditure | -139 | -130 | -91 | -2 | -2 |
| Free Cash Flow | -1,005 | -2,434 | -1,598 | -4,708 | -2,771 |